Emilie D. Duchesneau

Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis

Hongbo Yang, Emilie D. Duchesneau, Rebekah Foster et al. · Journal of Medical Economics · 2017 · 32 citations

The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example

Emilie D. Duchesneau, Bradford E. Jackson, Michael Webster‐Clark et al. · Cancer Epidemiology Biomarkers & Prevention · 2022 · 28 citations · Full text

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma

Elyse Swallow, Andrew Messali, Sameer R. Ghate et al. · Journal of Managed Care & Specialty Pharmacy · 2018 · 21 citations · Full text

Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis

Parinaz Ghaswalla, Brandon J. Patterson, Wendy Y. Cheng et al. · Human Vaccines & Immunotherapeutics · 2018 · 19 citations · Full text

Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer

Selena J. An, Emilie D. Duchesneau, Paula D. Strassle et al. · npj Breast Cancer · 2022 · 17 citations · Full text